文献速递胃肠动力与功能性疾病

多中心、双盲、随机、安慰剂对照、平行组研究:评估益生菌婴儿双歧杆菌35624对有腹部不适和腹胀症状的非患者人群的获益

Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating.
PubMed 文献 · Am J Gastroenterol · 2016-11-15

在美国10个临床中心开展双盲随机安慰剂对照平行研究,302例每周至少2次腹部不适或腹胀、近12个月未因症状就诊或用药的普通人群受试者,先接受2周安慰剂导入,再接受4周干预(婴儿双歧杆菌35624每日10^9 c.f.u.)。275例可评估;两组腹部不适与腹胀严重度均较基线显著改善(P<0.05),但干预结束时益生菌组与安慰剂组在腹部不适和腹胀严重度上均无显著差异(P>0.3);婴儿双歧杆菌35624组无腹胀天数多于安慰剂组(P<0.05);两种方案耐受良好。

要点

  • 非患者人群中,婴儿双歧杆菌35624未显著改善腹部不适和腹胀的平均严重度。
  • 两组症状严重度较基线均显著改善(P<0.05),干预结束时组间无显著差异(P>0.3)。
  • 婴儿双歧杆菌35624组无腹胀天数多于安慰剂组(P<0.05),两种方案耐受良好。

核心结论

  • 与既往在肠易激综合征患者中的临床研究不同,婴儿双歧杆菌35624在非患者人群中未显著改善腹部不适和腹胀症状的平均严重度。
  • 作者认为这一结果可能由较高的安慰剂效应以及功能性肠道症状在非患者人群中影响较低所解释。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照、平行组研究,含2周安慰剂导入期和4周干预期,在美国10个临床中心开展。
  • 受试者经广告从普通人群中招募,随机302例,症状为每周至少2次腹部不适和腹胀、持续至少3个月,且近12个月未因症状就诊或接受处方药物治疗。
  • 275例受试者提供可评估数据,平均年龄42岁,女性79%,白人74%。
  • 干预为婴儿双歧杆菌35624每日10^9 c.f.u.。
  • 采用6点Likert量表(0=无,5=非常严重)评估症状严重度,并以无症状天数评估症状频率。

主要发现

  • 基线时腹部不适平均严重度评分为2.4,腹胀为2.5,安慰剂组与益生菌组间无显著差异。
  • 两组在4周干预期间腹部不适和腹胀评分均较基线显著改善(P<0.05)。
  • 干预结束时,益生菌组与安慰剂组在腹部不适和腹胀的平均严重度评分上均无显著差异(P>0.3)。
  • 婴儿双歧杆菌35624组无腹胀天数多于安慰剂组(P<0.05)。
  • 两种方案均耐受良好。

临床怎么用

  • 作者认为,在非患者人群中,婴儿双歧杆菌35624未显著改善腹部不适和腹胀的平均严重度;原文未据此给出推荐。

局限性

  • 作者认为结果可能由较高的安慰剂效应以及功能性肠道症状在非患者人群中影响较低所解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Bifidobacterium infantis 35624 is a probiotic that is used often in patients with irritable bowel syndrome (IBS). Non-patients with bowel symptoms may differ from patients with IBS in the impact of their bowel symptoms on illness severity, healthcare and treatment seeking behavior. The aim of this study is to assess the efficacy of B. infantis 35624 (109 c.f.u. per day) for the relief of abdominal discomfort and bloating in a non-patient population. METHODS: A double-blind, randomized, placebo-controlled, parallel study with a 2-week placebo run-in phase followed by a 4-week intervention phase was conducted at ten clinical centers (USA). Subjects were recruited from the general population by advertisement. The study randomized 302 subjects who experienced abdominal discomfort and bloating ≥2-times per week for at least three months but have not seen a physician or received prescribed medication for their symptoms in the past 12 months. Subjects were assessed for pre- to post-intervention changes in symptom severity (on a 6-point Likert scale; 0=none, 5=very severe) and frequency (symptoms-free days). RESULTS: A total of 275 subjects (mean age 42 years, 79% female, 74% Caucasian) provided evaluable data. Overall mean severity scores at baseline were 2.4 for abdominal discomfort and 2.5 for bloating with no significant differences between the placebo and probiotic groups. Both groups showed significant (P<0.05) improvement in abdominal discomfort and bloating scores over the 4-week intervention period. Mean severity symptom scores at the end of intervention showed no significant differences between the probiotic and the placebo groups in either abdominal discomfort or bloating (P>0.3). The frequency of abdominal bloating-free days was greater in the B. infantis 35624 group compared to the placebo group (P<0.05). Both regimens were well tolerated. CONCLUSIONS: Unlike previous clinical studies in patients with IBS, B. infantis 35624 did not show a significant improvement in the mean severity of symptoms of abdominal discomfort and bloating in a non-patient population. This may be explained by the high placebo effect and the lower impact of functional bowel symptoms in the non-patient population.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ringel-Kulka T, McRorie J, Ringel Y, et al. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating. Am J Gastroenterol. 2016. PMID: 27845337. doi:10.1038/ajg.2016.511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。